Jason Westin: Targeted therapy combinations are safe and effective as an initial treatment for patients with Large B-cell Lymphoma

Jason Westin, Director of Clinical Research and Section Chief of Aggressive Lymphoma at MD Anderson Cancer Centre, shared the following on LinkedIn:

“I was honored to present our investigator initiated trial at the 2023 ASH Annual meeting. We showed that targeted therapy combinations are safe and effective as an initial treatment for patients with Large B-cell Lymphoma, and may allow for reducing or removing the need for chemotherapy. LTRA (lenalidomide, tafasitamab, rituximab, and acalabrutinib) had a complete response rate of 63% prior to chemotherapy, and 100% at end of treatment with our response adapted approach. Progress!”

For details click here.
Source: Jason Westin/LinkedIn